Loading
NASDAQHealthcareBiotechnology
Latest quote
$30.00
+$12.00 · +66.67%
Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.
Previous close
$30.00
+$12.00 · +66.67%
Regular session · ET · Market data may be delayed.
Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.
Day range
Current $30.00
52-week range
Current $30.00
Regular session · ET · Market data may be delayed.
Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.
Day range
Current $30.00
52-week range
Current $30.00
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
